Rhomboid-like pseudoproteases are a conserved superfamily of proteins related to the rhomboid intramembrane serine proteases that lack key catalytic residues. iRhom2, a member of the rhomboid-like pseudoprotease superfamily, regulates the maturation and trafficking of ADAM17 and is associated with inflammatory arthritis. Recent studies demonstrate that iRhom2 is also involved in innate immunity by regulating the trafficking and stability of MITA (also called STING), which is a central adaptor in innate antiviral signalling pathways. Here, we summarize recent progress on the roles and mechanisms of iRhom2 and its homologues in innate immunity and also discuss the links between the physiological functions of iRhoms and immunological diseases.
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Rhomboids are intramembrane serine proteases that are present in most prokaryotes and all eukaryotes and have the unique ability to cleave membrane proteins as a result of their catalytic residues embedded in the lipid bilayer [1] . The first superfamily member of rhomboid-like proteases was discovered in Drosophila melanogaster, where it plays a key regulatory role in epidermal growth factor receptor (EGFR) signalling [2] . Drosophila rhomboids trigger the release of growth factors such as Spitz, Gurken and Keren via a specific cut in the transmembrane anchor [2] [3] [4] . Soon after the discovery of rhomboid proteases, inactive homologues lacking essential catalytic residues were identified by bioinformatics analysis [5, 6] . Most genes encoding these inactive homologues are well conserved in different species, suggesting that a selective pressure exists to retain these inactive enzymes with potential importance for life in a proteolytic-independent manner [6] . Interestingly, a rhomboid protease with disabled catalytic activity does not covert into an inactive rhomboid (iRhom)-like protein, suggesting that additional domains are important for its functions [7] . Compared with rhomboid proteases that have six or seven transmembrane domains (TMDs), their inactive homologues are extended by an extra N-or C-terminal TMD and/or extramembrane domains. These extra domains enable a greater number of possible functions for rhomboid-like pseudoproteases [8] .
Currently, two distinct families of rhomboid-like pseudoproteases have been investigated: iRhoms and derlins [8] [9] [10] . The other rhomboid-like pseudoproteases, such as UBAC2, RHBDDs and TMEM115, have not been functionally characterized to date [1, 8, [11] [12] [13] [14] . iRhoms contain two members, iRhom1
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and iRhom2, and both have an extended cytoplasmic amino terminus and a highly conserved Cys-rich luminal loop domain between the first two TMDs, termed the iRhom homology domain [8] . iRhom2 has important roles in the regulation of EGFR and tumour necrosis factor (TNF) signalling pathways with respect to facilitating the maturation and trafficking of ADAM17 [7, [15] [16] [17] [18] [19] . Recent studies report that iRhom2 regulates innate immunity to DNA viruses by facilitating the cellular trafficking and stability of MITA (also called STING), which is a central adaptor in innate antiviral signalling pathways [20] . Furthermore, human cytomegalovirus (HCMV) tegument protein UL82 has been reported to inhibit iRhom2-mediated MITA trafficking to evade the host innate immune response [21] . In this review, we summarize recent developments regarding the roles of iRhoms and other rhomboid-like pseudoproteases in innate immune responses and related immunological diseases.
Rhomboid-like pseudoproteases in inflammatory responses
Tumour necrosis factor is an important inflammatory cytokine that is crucial both for effective inflammatory responses and inflammatory diseases, including sepsis, Crohn's disease, psoriasis and rheumatoid arthritis [22] [23] [24] . TNF is synthesized as a membrane-bound precursor. Its ectodomain is shed from cells after cleavage by ADAM17 [25, 26] . Recently, two studies in mice have shown that ADAM17 is a client of mammalian iRhoms [15, 16] . Instead of resulting in the degradation of their clients in Drosopila [7] , mammalian iRhoms license trafficking of clients from the endoplasmic reticulum (ER) to the Golgi apparatus ( Fig. 1) [15] [16] [17] . ADAM17 fails to exit from the ER in iRhom2-deficient mice, which prevents furin-mediated maturation and trafficking of ADAM17 to the cell surface where TNF is cleaved and released [15, 16] . Consistent with this, iRhom2-deficient mice barely secrete TNF in response to lipopolysaccharide (LPS) or Listeria, although interleukin (IL)-1b, IL-6 and IL-12 are induced normally in these mice [15, 16] . Moreover, RNA and protein levels of TNF are unaffected in iRhom2 À/À macrophages [15] . These results suggest that iRhom2-deficiency does not impair the induction of TNF but instead results in a shedding failure. More recent studies demonstrate that iRhom2 has no effects on the expression of LPS-induced downstream genes, including Tnf, Isg56 and Ifnb1 [20] . However, another study reports that iRhom2 is also involved in LPSinduced Toll-like receptor (TLR)4-nuclear factorkappa B (NF-jB) signalling [27] . In the later study, knockdown of iRhom2 reduces phosphorylated IjB levels and NF-jB activation [27] . This suggests that other clients may exist in upstream of TNF shedding. Interestingly, iRhom2 is markedly up-regulated in cells treated with LPS [27] . In light of the observation that iRhom2 expression is also up-regulated by TNF [16] , Fig. 1 . iRhoms regulate the trafficking and maturation of ADAM17. iRhom2 binds to immature ADAM17 in the ER, which promotes its exit from the ER (1). In the Golgi (2), ADAM17 undergoes furinmediated maturation and activation. iRhom2 and mature ADAM17 are in complex with one another at the plasma membrane (3). The iRhom2 N-terminus stabilizes mature ADAM17 at the cell surface where it cleaves TNF and EGFR.
this implies a positive-feedback regulatory role for iRhom2 in the LPS-and TNF-induced inflammatory responses. Different members derived from a superfamily often act in the same signalling pathway through synergism or antagonism. Unlike iRhom2, another iRhom-like protein called Rhbdd3 has been identified as an inhibitor for TLR-triggered activation of NF-jB and the induction of IL-6 in dendritic cells (DCs) [28] . Rhbdd3 binds to K27-linked polyubiquitination chains of NFkB essential modulator (NEMO) and recruits A20 to deubiquitinate K63-linked polyubiquitination of NEMO, leading to the suppression of TLR-triggered activation of NF-jB and induction of IL-6 in DCs [28] . Unlike iRhom2, which is located at the ER and Golgi apparatus, Rhbdd3 is mostly localized in the endosomes where it interacts with NEMO [28] . These suggest that distinct membrane localizations of iRhoms may be responsible for their diverse clients and physiological functions. Rhbdd3 is also found to be highly induced by LPS in bone marrow-derived DCs [28] . Interestingly, another study shows that Rhbdd3 is selectively up-regulated in natural killer (NK) cells treated with poly(I:C), a ligand for TLR3 [29] . Mechanistically, Rhbdd3 interacts with and promotes the degradation of DAP12, which is a key intracellular accessory adaptor for several activating receptors on NK cells, leading to the inhibition of TLR3-mediated NK cell activation [29] . It has also been reporetd that Rhbdd3 attenuates TLR3-triggered acute inflammation by controlling NK cell activation and accumulation in the livers and disrupting the NK-Kupffer cell interaction [29] . Collectively, these studies suggest that different rhomboid-like pseudoproteases play positive or negative feedback regulatory roles in inflammatory responses triggered by different stimuli. It would be interesting to investigate whether iRhom2 and Rhbdd3 regulate inflammatory responses at different stages and ensure inflammatory homeostasis in distinct cells. Whether other rhomboid-like pseudoproteases are involved in inflammatory responses also requires further investigation.
iRhom2 in innate antiviral immunity
Type I interferons (IFNs) and TNF are crucial for innate antiviral immune and inflammatory responses, which defend against pathogen infection. Recently, the roles of iRhom2 in innate antiviral responses have begun to emerge [20, 21] . iRhom2 was identified as a positive regulator for innate antiviral responses to DNA viruses via expression cloning [20] . Mechanistically, iRhom2 interacts with MITA, which is an ERassociated central adaptor in viral DNA-triggered innate immune signalling pathways [30] [31] [32] . Interestingly, similar to iRhom2-mediated trafficking of ADAM17, iRhom2 is required for the translocation of MITA from the ER to the Golgi apparatus and further to perinuclear aggregates or microsomes in response to DNA stimulation, which is essential for the activation of MITA and the induction of downstream antiviral genes [32, 33] . Notably, iRhom2 is upregulated by viruses in various cell types [20] . Confocal microscopy analysis indicates that iRhom2 is colocalized with MITA in the ER, and both are translocated from the ER via the ER-Golgi intermediate compartment (ERGIC)/Golgi apparatus to perinuclear microsomes upon herpes simplex virus (HSV)-1 infection [20] . MITA is restricted in the ER in iRhom2 À/À cells upon viral infection, suggesting that iRhom2 is required for exit of MITA from the ER [20] . iRhom2 interacts with the translocon component, transloconassociated protein (TRAP)b, and promotes the association of MITA with TRAPb [20] . Knockdown of TRAPb markedly inhibits MITA trafficking and the induction of downstream antiviral genes [20] . These observations suggest that iRhom2 escorts MITA translocation from the ER to the Golgi apparatus by promoting the assembly of MITA-TRAPb translocation complexes. iRhom2 is also found to partially localize in the lysosomes [20] , suggesting that iRhom2 plays an unknown role in lysosomes.
In addition to a role in regulating MITA translocation, iRhom2 also regulates the stability of MITA [20] . Because iRhom2 is partially localized in the lysosomes and MITA has been reported to undergo lysosomemediated degradation after DNA viral infection [34] , it was proposed that iRhom2 is involved in lysosomemediated degradation of MITA. However, the proteasome inhibitor MG132, but not the lysosome inhibitor NH 4 Cl, markedly inhibits the down-regulation of MITA in iRhom2-deficient cells [20] , suggesting that iRhom2 regulates the proteasome-dependent degradation of MITA. Furthermore, iRhom2 indirectly promotes the removal of K48-linked polyubiquitination of MITA in uninfected and early-infected cells [20] . Given that iRhom2 is not a deubiquitinase, the simplest hypothesis is that iRhom2 functions as an adaptor to recruit a deubiquitinase to MITA. Biochemical screens have identified EIF3S5 as a deubiquitinase that targets MITA [20] . Knockdown of EIF3S5 increases K48-linked polyubiquitination of MITA in uninfected and early-infected cells. Consistently, knockdown of EIF3S5 inhibits HSV-triggered signalling and the synergetic effects of iRhom2 on MITA-mediated induction of downstream antiviral genes [20] . These results suggest that iRhom2 links EIF3S5 to MITA and promotes the deubiquitination and stability of MITA. As noted above, Rhbdd3 removes K63-linked polyubiquitination of NEMO by recruiting the deubiquitinase A20 [28] . These studies suggest that the recruitment of deubiquitinases may serve as a conserved strategy by which rhomboid-like pseudoproteases regulate their clients.
On the basis of these findings, we propose a working model for the iRhom2-mediated regulation of MITA activities in innate antiviral responses to DNA viruses. In resting cells, iRhom2 constitutively interacts with MITA and EIF3S5 in the ER. In these complexes, EIF3S5 constitutively deubiquitinates MITA and prevents its degradation via the proteasomal pathways. Following infection by DNA virus, iRhom2 links MITA to the TRAPb translocator, which facilitates the trafficking of MITA to the Golgi apparatus and further to the perinuclear microsomes. During the trafficking processes, TBK1 and IRF3 are recruited to the MITA complexes, leading to their activation and the induction of downstream antiviral genes (Fig. 2) .
Rhomboid-like pseudoproteases in immune evasion
Previous studies demonstrate that the trafficking of MITA is essential for its activation and the recruitment of downstream TBK1 and IRF3, leading to the induction of type I IFNs and other antiviral proteins for efficient innate immune responses against viral invasion [30] [31] [32] . Consistent with the importance of MITA trafficking in antiviral response, recent studies show that iRhom2-mediated MITA trafficking is antagonized by pathogenic viruses as an escape strategy with respect to antiviral responses [21, 33] . HCMV tegument protein UL82 inhibits the assembly of the MITA-iRhom2-TRAPb complex, and impairs MITA trafficking from the ER to the Golgi apparatus and its recruitment of TBK1 and IRF3, leading to blockade of host antiviral immune responses [21] . It is interesting to note that UL82 selectively inhibits iRhom2-mediated trafficking but not the stability of MITA [21] . Additionally, a recent study reported that Shigella effector IpaJ inhibits the innate immune response by blocking MITA translocation from the ER to ERGIC/ Golgi [33] . However, whether IpaJ targets iRhom2 remains unknown. Consistently, iRhom2 À/À mice are more susceptible to lethal HSV-1 and Listeria monocytogenes infection [16, 20] . These studies suggest that iRhom2 is a target for the immune evasion of pathogenic microbes.
In addition to acting as a target attacked by viruses, rhomboid-like pseudoproteases are hijacked by viruses to antagonize host antiviral immune responses [35, 36] . Derlin-1 is an iRhom-like protein that is required for the dislocation of misfolded or unwanted proteins from the ER to cytosol and it is essential for ER-associated degradation (ERAD) of its clients [10] . The ERAD pathway is an evolutionarily conserved protein quality control mechanism that removes misfolded and damaged proteins from the ER or controls the abundance of properly folded proteins [37, 38] . Interestingly, many viruses use ERAD to down-regulate components of the immune system and escape from immune responses [39] . HCMV proteins US2 and US11 hijack Derlin-1 to initiate the ERAD of newly synthesized MHC class I heavy chains, which contributes to the immune evasion of HCMV [35, 36] . Furthermore, parasite rhomboid proteases also play important roles in their survival and host cell invasion [40] .
Collectively, these findings suggest that iRhommediated translocation and ERAD of membrane proteins may serve as an important strategy for the immune evasion of microbes, implying that the functions of iRhoms in immunity are evolutionarily conserved. These findings suggest that these 'dead' enzymes may serve as potential therapeutic targets for infectious and immunological diseases.
Rhomboid-like pseudoproteases in autoimmune or chronic inflammatory diseases
Although iRhoms have no protease activity, they regulate the secretion of several ligands of EGFR and the proinflammatory cytokine TNF, as well as the trafficking and stability of MITA [15, 16, 20] . Therefore, iRhoms can activate the EGFR signalling pathway, as well as inflammation and antiviral immune responses, and all of these are involved in a broad spectrum of human diseases [41] .
As a primary trigger of inflammatory responses, TNF is associated with many human diseases, including rheumatoid arthritis, Crohn's disease, atherosclerosis, psoriasis, sepsis, diabetes and obesity [22] [23] [24] . Studies have demonstrated that iRhom2 and myeloidexpressed ADAM17 play critical roles in inflammatory arthritis, indicating that iRhom2 is a potential therapeutic target for the selective inactivation of ADAM17 in myeloid cells [42] . Interestingly, similar to iRhom2, Rhbdd3 appears to be involved in rheumatoid arthritis, although it plays an inhibitory role in the TLRmediated production of IL-6, which is another important proinflammatory cytokine [29] . According to publically available gene-profiling data, Rhbdd3 expression is significantly down-regulated in macrophages present in the synovial fluid from patients with rheumatoid arthritis [43] . Moreover, Rhbdd3 expression is also lower in the colonic mucosal tissues of patients with ulcerative colitis and Crohn's disease, as well as in the ileum tissues of patients with Crohn's disease. In addition, Rhbdd3 À/À mice are prone to developing autoimmune disorders [28, 29] . All of this evidence taken together suggests a link between Rhbdd3 and autoimmune or chronic inflammatory diseases. The trafficking of MITA is essential for its activation, whereas persistent MITA activation results in autoimmune disease. Clinical and genetic studies of patients exhibiting autoinflammatory vasculopathy and autoimmunity have identified three single residue mutations of MITA that cause constitutive ER exit and ligand-independent activation of MITA, indicating that a disorder of MITA translocation contributes to autoinflammatory and autoimmune diseases [33, 44, 45] . Indeed, there is concomitant overproduction and accumulation of type I IFNs and TNF in most autoimmune and autoinflammatory patients. Therefore, inhibitors of iRhom2 may simultaneously block the overproduction of type I IFNs and TNF by inhibiting the translocation of MITA and ADAM17, respectively, and therefore they can serve as efficient drugs for various autoimmune diseases.
Proinflammatory cytokines such as TNF and IL-6 can enhance tumour progression by providing an inflammatory microenvironment [46] . In addition, EGFR signalling also affects tumour growth [46] . Consistent with such an important role in the secretion of proinflammatory cytokines and EGFR signalling, deregulation of iRhom2 levels was shown to affect carcinogenesis and tumour growth. High throughput sequencing has revealed that missense mutations in the iRhom2 gene cause tylosis esophageal cancer [47, 48] . Recent evidence shows that these tylosis esophageal cancer-associated mutations in the iRhom2 gene induce ADAM17 activation in epidermal keratinocytes, resulting in an increased shedding of ADAM17 substrates, including EGF family growth factors and pro-inflammatory cytokines [49] . Other iRhom2 mutations may play a role in ovarian cancer [50] . In addition, iRhom1 was shown to be associated with squamous epithelial and breast cancers [51, 52] , whereas Rhbdd3 plays a significant role in the development of hepatocellular carcinoma by inhibiting TLR-triggered acute liver injury [29] . Fig. 2 . Roles of iRhom2 in innate immunity. In uninfected cells, iRhom2 constitutively interacts with MITA and EIF3S5 in the ER. In these complexes, EIF3S5 deubiquitinates MITA (1) and prevents its degradation via the proteasomal pathways (2) . Following infection by DNA virus, iRhom2 links MITA to the TRAPb translocator, which facilitates trafficking of MITA from the ER to the Golgi apparatus and perinuclear microsomes (3) . During the trafficking processes, MITA recruits downstream kinase TBK1 to phosphorylate transcription factor IRF3. The activated IRF3 translocates into the nucleus to initiate the transcription of downstream antiviral genes (4). By contrast, HCMV tegument protein UL82 inhibits iRhom2-mediated MITA trafficking to evade host defence (5).
In conclusion, these observations suggest that both iRhoms and its paralogues are associated with the pathogenesis of several human diseases, including auto-immune/inflammatory diseases and cancer, and may serve as new targets for both prevention and intervention with respect to these diseases.
Conclusions and perspectives
Previous studies have established that iRhom2 is necessary for the maturation and trafficking of ADAM17 from the ER to cell surface, which facilitates LPS-and Listeria-induced TNF shedding [15, 16] . Recent studies have also established a role of iRhom2 in MITA trafficking from the ER to perinuclear microsomes, which is responsible for the MITA-mediated innate immune responses to DNA viruses [20] . These studies indicate that iRhom2 may have a wide role in regulating membrane protein trafficking. Although iRhoms have no protease activity, they retain the ability to interact with membrane-spanning proteins and decide the fates of their clients. It is not clear how iRhoms make decisions about whether their clients are exported, degraded or stabilized. It is possible that the structural properties of the clients dictate the actions chosen by a specific iRhom protein.
Excessive and persistent innate immune and inflammatory responses are harmful to the host. It is unknown how iRhom2-mediated innate immune and inflammatory responses are abated and terminated. Recent studies have shown that iRhom2 is regulated and phosphorylated by protein kinase G and extracellular signal-regulated kinases 1/2 [53, 54] , suggesting that iRhom2 is regulated by post-translational modifications. In addition, iRhom2 is found to partially localize in the lysosomes [20] , suggesting that iRhom2 may be directly degraded by lysosomal or other mechanisms. Alternatively, activation of iRhom2-mediated signalling may be terminated independently of targeting iRhom2. For example, it has been demonstrated that Atg9a negatively regulates DNA-induced immune responses by inhibiting the dynamic translocation of MITA [55] . It has also been shown that ULK1 phosphorylates MITA at S366 and causes the degradation of MITA, thereby preventing persistent innate immune responses [34] .
One important clue about the possible roles of iRhom2 in the brain has emerged recently from a study reporting an association between the methylation status of iRhom2 gene and Alzheimer's disease (AD) [56] . Interestingly, elevated levels of TNF have been observed in the brain with AD and brain injury, which may cause neuroinflammation [57] . These clues lead to the speculation that de-methylation of the iRhom2 gene may increase the expression of iRhom2 and subsequently enhance ADAM17-dependent shedding of TNF or other substrates, thereby exacerbating the inflammatory components of AD. HSV-1 is a neurotropic virus and the leading cause of sporadic viral encephalitis. The iRhom2-MITA axis plays a critical role in protecting the host from lethal HSV-1 infection [58, 59] . Therefore, iRhom2 may serve as an attractive therapeutic target in brain diseases resulting from infections and neuroinflammation.
